For human clinical trials, there is a growing movement to replace the term "study subject" with a terminology that is more respectful and recognizes the agency of those who consent to be treated and have their data collected. The term "participant”, rather than "study subject", is now used in ICH E6 R3 guidelines. The TransCelerate Biopharma Common Protocol Template states that "participant" may be used in patient-facing documents.
Japan Clinical Informatization for Chronic Diseases Related to Lifestyle
Japan Clinical Informatization for Chronic Diseases Related to Lifestyle
Japan Clinical Informatization for Chronic Diseases Related to Lifestyle
Japan Clinical Informatization for Chronic Diseases Related to Lifestyle
Japan Clinical Informatization for Chronic Diseases Related to Lifestyle
Japan Clinical Informatization for Chronic Diseases Related to Lifestyle
The CDISC Analysis Data Model Implementation Guide (ADaMIG) provides several timing variables for modeling clinical trial designs in analysis datasets. APHASE, APERIOD, and ASPER can be used in conjunction with related treatment variables to meet a variety of analysis requirements, from single-period parallel studies to much more complicated situations involving multiple treatment periods and even different studies. The goal of this article is to provide guidelines for identifying when to use the different timing variables that are available. Additional examples can be found in the References and Resources listed at the end of the article.